Cargando…

The effect of alendronate on lipid profile of postmenopausal women with osteopenia and prediabetes: A randomized triple-blind clinical trial

BACKGROUND: Prediabetes is a high-risk state for developing diabetes at an annual rate of 5%–10%. Early intervention can prevent further complications, including metabolic syndrome. Bisphosphonates are commonly used for osteoporotic postmenopausal women. The purpose of this study was to assess the e...

Descripción completa

Detalles Bibliográficos
Autores principales: Karimifard, Maryam, Aminorroaya, Ashraf, Amini, Massoud, Kachuie, Ali, Feizi, Awat, Yamini, Sima Aminorroaya, Alijanvand, Moluk Hadi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506247/
https://www.ncbi.nlm.nih.gov/pubmed/34729060
http://dx.doi.org/10.4103/jrms.JRMS_579_19
_version_ 1784581698078375936
author Karimifard, Maryam
Aminorroaya, Ashraf
Amini, Massoud
Kachuie, Ali
Feizi, Awat
Yamini, Sima Aminorroaya
Alijanvand, Moluk Hadi
author_facet Karimifard, Maryam
Aminorroaya, Ashraf
Amini, Massoud
Kachuie, Ali
Feizi, Awat
Yamini, Sima Aminorroaya
Alijanvand, Moluk Hadi
author_sort Karimifard, Maryam
collection PubMed
description BACKGROUND: Prediabetes is a high-risk state for developing diabetes at an annual rate of 5%–10%. Early intervention can prevent further complications, including metabolic syndrome. Bisphosphonates are commonly used for osteoporotic postmenopausal women. The purpose of this study was to assess the effects of bisphosphonates on lipid profile including triglyceride (TG), total cholesterol, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) of prediabetic postmenopausal women with osteopenia. MATERIALS AND METHODS: In this triple-blind randomized controlled trial, sixty prediabetic, postmenopausal women with sufficient Vitamin D and osteopenia, aged 45–60 years, were randomly enrolled in two groups of intervention (receiving 70-mg alendronate for 12 weeks [duration for maximum metabolic effect of bisphosphonates], n = 30) and control (receiving placebo, n = 30) according to a randomized block procedure of size 2 and 1:1 allocation ratio. The primary outcome of the study, the lipid profile, was evaluated before and after the interventions. The effect of the intervention was assessed using analysis of covariance. RESULTS: The lipid profiles showed no significant differences to the mean values at the baseline in both the groups (all P > 0.05). At the end of the study, the differences between the groups were not significant for 25(OH) D(3) (mean difference: −11.09, 95% confidence interval: −32.43–10.25), T (4.19, −30.58–38.97), cholesterol (8.13, −13.07–29.33), LDL-cholesterol (5.07, −10.18–20.31), and HDL-cholesterol (−0.86, −6.04–4.31) when the baseline values and confounders were adjusted (all P > 0.05). CONCLUSION: No statistically significant difference was detected in the serum lipid profile of prediabetic postmenopausal women with osteopenia as a result of alendronate intervention. More studies with larger sample sizes and longer intervention periods are recommended.
format Online
Article
Text
id pubmed-8506247
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-85062472021-11-01 The effect of alendronate on lipid profile of postmenopausal women with osteopenia and prediabetes: A randomized triple-blind clinical trial Karimifard, Maryam Aminorroaya, Ashraf Amini, Massoud Kachuie, Ali Feizi, Awat Yamini, Sima Aminorroaya Alijanvand, Moluk Hadi J Res Med Sci Original Article BACKGROUND: Prediabetes is a high-risk state for developing diabetes at an annual rate of 5%–10%. Early intervention can prevent further complications, including metabolic syndrome. Bisphosphonates are commonly used for osteoporotic postmenopausal women. The purpose of this study was to assess the effects of bisphosphonates on lipid profile including triglyceride (TG), total cholesterol, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) of prediabetic postmenopausal women with osteopenia. MATERIALS AND METHODS: In this triple-blind randomized controlled trial, sixty prediabetic, postmenopausal women with sufficient Vitamin D and osteopenia, aged 45–60 years, were randomly enrolled in two groups of intervention (receiving 70-mg alendronate for 12 weeks [duration for maximum metabolic effect of bisphosphonates], n = 30) and control (receiving placebo, n = 30) according to a randomized block procedure of size 2 and 1:1 allocation ratio. The primary outcome of the study, the lipid profile, was evaluated before and after the interventions. The effect of the intervention was assessed using analysis of covariance. RESULTS: The lipid profiles showed no significant differences to the mean values at the baseline in both the groups (all P > 0.05). At the end of the study, the differences between the groups were not significant for 25(OH) D(3) (mean difference: −11.09, 95% confidence interval: −32.43–10.25), T (4.19, −30.58–38.97), cholesterol (8.13, −13.07–29.33), LDL-cholesterol (5.07, −10.18–20.31), and HDL-cholesterol (−0.86, −6.04–4.31) when the baseline values and confounders were adjusted (all P > 0.05). CONCLUSION: No statistically significant difference was detected in the serum lipid profile of prediabetic postmenopausal women with osteopenia as a result of alendronate intervention. More studies with larger sample sizes and longer intervention periods are recommended. Wolters Kluwer - Medknow 2021-08-30 /pmc/articles/PMC8506247/ /pubmed/34729060 http://dx.doi.org/10.4103/jrms.JRMS_579_19 Text en Copyright: © 2021 Journal of Research in Medical Sciences https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Karimifard, Maryam
Aminorroaya, Ashraf
Amini, Massoud
Kachuie, Ali
Feizi, Awat
Yamini, Sima Aminorroaya
Alijanvand, Moluk Hadi
The effect of alendronate on lipid profile of postmenopausal women with osteopenia and prediabetes: A randomized triple-blind clinical trial
title The effect of alendronate on lipid profile of postmenopausal women with osteopenia and prediabetes: A randomized triple-blind clinical trial
title_full The effect of alendronate on lipid profile of postmenopausal women with osteopenia and prediabetes: A randomized triple-blind clinical trial
title_fullStr The effect of alendronate on lipid profile of postmenopausal women with osteopenia and prediabetes: A randomized triple-blind clinical trial
title_full_unstemmed The effect of alendronate on lipid profile of postmenopausal women with osteopenia and prediabetes: A randomized triple-blind clinical trial
title_short The effect of alendronate on lipid profile of postmenopausal women with osteopenia and prediabetes: A randomized triple-blind clinical trial
title_sort effect of alendronate on lipid profile of postmenopausal women with osteopenia and prediabetes: a randomized triple-blind clinical trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506247/
https://www.ncbi.nlm.nih.gov/pubmed/34729060
http://dx.doi.org/10.4103/jrms.JRMS_579_19
work_keys_str_mv AT karimifardmaryam theeffectofalendronateonlipidprofileofpostmenopausalwomenwithosteopeniaandprediabetesarandomizedtripleblindclinicaltrial
AT aminorroayaashraf theeffectofalendronateonlipidprofileofpostmenopausalwomenwithosteopeniaandprediabetesarandomizedtripleblindclinicaltrial
AT aminimassoud theeffectofalendronateonlipidprofileofpostmenopausalwomenwithosteopeniaandprediabetesarandomizedtripleblindclinicaltrial
AT kachuieali theeffectofalendronateonlipidprofileofpostmenopausalwomenwithosteopeniaandprediabetesarandomizedtripleblindclinicaltrial
AT feiziawat theeffectofalendronateonlipidprofileofpostmenopausalwomenwithosteopeniaandprediabetesarandomizedtripleblindclinicaltrial
AT yaminisimaaminorroaya theeffectofalendronateonlipidprofileofpostmenopausalwomenwithosteopeniaandprediabetesarandomizedtripleblindclinicaltrial
AT alijanvandmolukhadi theeffectofalendronateonlipidprofileofpostmenopausalwomenwithosteopeniaandprediabetesarandomizedtripleblindclinicaltrial
AT karimifardmaryam effectofalendronateonlipidprofileofpostmenopausalwomenwithosteopeniaandprediabetesarandomizedtripleblindclinicaltrial
AT aminorroayaashraf effectofalendronateonlipidprofileofpostmenopausalwomenwithosteopeniaandprediabetesarandomizedtripleblindclinicaltrial
AT aminimassoud effectofalendronateonlipidprofileofpostmenopausalwomenwithosteopeniaandprediabetesarandomizedtripleblindclinicaltrial
AT kachuieali effectofalendronateonlipidprofileofpostmenopausalwomenwithosteopeniaandprediabetesarandomizedtripleblindclinicaltrial
AT feiziawat effectofalendronateonlipidprofileofpostmenopausalwomenwithosteopeniaandprediabetesarandomizedtripleblindclinicaltrial
AT yaminisimaaminorroaya effectofalendronateonlipidprofileofpostmenopausalwomenwithosteopeniaandprediabetesarandomizedtripleblindclinicaltrial
AT alijanvandmolukhadi effectofalendronateonlipidprofileofpostmenopausalwomenwithosteopeniaandprediabetesarandomizedtripleblindclinicaltrial